This week has brought news of new superbugs--daptomycin-resistant VRE (Vancomycin-resistant Enterococcus) isolates and linezolid-resistant MRSA.
I've cared for patients this week with MRSA, VRE, and ESBL gram-negative rods resistant to almost every antibiotic.
Many factors fuel the rise in resistant organisms. Some that are not often addressed include inadequate education (e.g. that asymptomatic Foley catheter related cultures should not be treated);
fear of peer review or legal liability for not treating a culture;
the demands of family or religious groups that “everything be done” even when the patient is clearly terminal and the treatment is futile—and where the treatment of one such patient puts many others at unnecessary risk.
A excellent overview of some of the other issues can be found at the Center for Global Development’s drug resistance site.
As an Infectious Disease physician who has been involved in clinical research for new antibiotics as well as patient care, I am very familiar with the difficulties of bringing a new drug to market. In fact, I participated in early clinical trials for both Daptomycin and Linezolid. It angers and saddens me to see these valuable and critical resources squandered by irresponsible detailing and prescribing patterns and because of liability concerns. We need serious guidelines and restrictions on antibiotic use if we are not to soon enter the post-antibiotic era. There is no time to wait for new drugs to be developed.